Medicus Pharma Ltd. (MDCX)
MDCX moved a median of -0.48% 30 minutes after news, and 0.00% by the close. How MDCX actually reacts to news — the realized, point-in-time move the market made, measured across 366 labeled events over the last three years with zero look-ahead.
MDCX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 328 |
| 30-min | -0.48% | 37% | 358 |
| 60-min | -0.79% | 36% | 361 |
| to close | 0.00% | 47% | 358 |
| Middle 50% of MDCX reactions | -2.60% to +1.86% |
|---|---|
| Median reaction (30-min) | -0.48% |
| Measured reactions | 366 |
Half of all Medicus Pharma Ltd. news events land between -2.60% and +1.86% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MDCX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 11 | -1.70% | 18% | -9.75% |
| Rating reiterations | 49 | -0.80% | 31% | -0.90% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how MDCX ranks against every other measured name →
That’s how MDCX usually reacts — get an email when it moves on news →Email me when MDCX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MDCX's baseline. Nothing else.
Recent MDCX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form PRE 14A Medicus Pharma Ltd. For: Dec 02 | SEC filing · Form PRE | SEC EDGAR | +0.96% | +4.62% | |
| Form 8-K Medicus Pharma Ltd. For: Oct 12 | SEC filing · Form 8-K | SEC EDGAR | +2.56% | -14.90% | |
| Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value | Press release | GlobeNewswire | -3.48% | -11.39% | |
| Form 8-K Medicus Pharma Ltd. For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | -3.48% | -11.39% | |
| Medicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer | Press release | GlobeNewswire | +0.07% | +3.71% | |
| Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment | Press release | GlobeNewswire | -1.65% | +0.59% | |
| Form 8-K Medicus Pharma Ltd. For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | -5.69% | -4.61% | |
| Form 8-K Medicus Pharma Ltd. For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | -3.13% | +1.63% | |
| Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose | Press release | GlobeNewswire | -2.68% | -6.05% | |
| Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company | Press release | GlobeNewswire | +0.00% | -1.16% | |
| Form 8-K Medicus Pharma Ltd. For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | -14.15% | -16.83% | |
| Form 10-Q Medicus Pharma Ltd. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.78% | +6.95% | |
| Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | -1.78% | +6.95% | |
| Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom | Press release | GlobeNewswire | -0.05% | +5.65% | |
| Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis | Press release | GlobeNewswire | +0.22% | -1.01% | |
| Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome | Press release | GlobeNewswire | -4.29% | -14.21% | |
| New to The Street to Broadcast Nationwide on Bloomberg Television Tonight at 6:30 PM ET Featuring RHINO Bitcoin, Marina Decisions, Medicus Pharma and Virtuix Holdings | Press release | ACCESS Newswire | -4.29% | -14.21% | |
| Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention | Press release | GlobeNewswire | +1.91% | +14.04% | |
| New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group | Press release | ACCESS Newswire | -1.87% | +7.48% | |
| Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026 | Press release | GlobeNewswire | -8.17% | -2.18% | |
| Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome | Press release | GlobeNewswire | -0.09% | -1.81% | |
| Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program | Press release | GlobeNewswire | -2.38% | +4.00% | |
| Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission | Press release | GlobeNewswire | -2.54% | -5.30% | |
| Form 8-K Medicus Pharma Ltd. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | +2.34% | |
| Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome | Press release | GlobeNewswire | +0.49% | +3.65% | |
| Medicus Pharma Announces $22 Million Non-Dilutive Financing | Press release | GlobeNewswire | -3.90% | -5.91% | |
| Form 8-K Medicus Pharma Ltd. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | -3.90% | -5.91% | |
| Form 10-Q Medicus Pharma Ltd. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.64% | -4.44% | |
| Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -0.64% | -4.44% | |
| Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response | Press release | GlobeNewswire | -0.20% | +8.62% | |
| Form ARS Medicus Pharma Ltd. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.52% | -5.17% | |
| Form DEF 14A Medicus Pharma Ltd. For: Jun 03 | SEC filing · Form DEF | SEC EDGAR | -0.04% | -0.56% | |
| Form 10-K/A Medicus Pharma Ltd. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.11% | -0.14% | |
| Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill | Press release | GlobeNewswire | -2.01% | +3.09% | |
| Form 8-K Medicus Pharma Ltd. For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | -2.01% | +3.09% | |
| Form PRE 14A Medicus Pharma Ltd. For: Jun 03 | SEC filing · Form PRE | SEC EDGAR | +0.09% | -3.62% | |
| Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome | Press release | GlobeNewswire | -0.52% | +14.06% | |
| Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression | Press release | GlobeNewswire | -0.63% | -29.74% | |
| New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms | Press release | ACCESS Newswire | +1.12% | -3.10% | |
| Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention | Press release | GlobeNewswire | +4.58% | +6.95% | |
| Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset | Press release | GlobeNewswire | -2.02% | -6.56% | |
| Form EFFECT Medicus Pharma Ltd. | SEC filing · Form EFFECT | SEC EDGAR | -4.59% | -7.59% | |
| Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate | Press release | GlobeNewswire | -4.59% | -7.59% | |
| Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan | Press release | GlobeNewswire | +1.62% | -6.86% | |
| Form 10-K Medicus Pharma Ltd. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.62% | -6.86% | |
| Form POS AM Medicus Pharma Ltd. | SEC filing · Form POS | SEC EDGAR | +1.62% | -6.86% | |
| Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update | Press release | ACCESS Newswire | +1.62% | -6.86% | |
| Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst | Press release | ACCESS Newswire | -3.08% | -3.08% | |
| Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26 | Press release | GlobeNewswire | -1.56% | -3.46% | |
| Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum | Press release | ACCESS Newswire | -5.49% | -4.24% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MDCX section they belong to.
Where else MDCX is measured.
MDCX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Medicus Pharma Ltd.'s median reaction calculated?
Every labeled MDCX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 366 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of MDCX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MDCX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.